secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-05-26T12:56:06+00:00
Accession:  0001193125-26-238059
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus reports CRB-701 42.9% cORR in 2L OPSCC at 3.6 mg/kg; registrational study planned summer 2026
--------------------------------------------------------------------------------

- cORR 42.9% (9/21) in 2L OPSCC at 3.6 mg/kg; median DOR 6.3 mo, PFS 5.6 mo.
- cORR 34.4% (11/32) in 2L cervical cancer at 3.6 mg/kg; 2 complete responses, DOR 8.0 mo.
- Safety: treatment discontinuations 2.8%; no Grade 5 events; ocular AEs manageable.
- FDA alignment on registrational trials: TEMPO-1 (OPSCC, n=250) to start summer 2026.
- 85.4% of OPSCC patients HPV+; 8 of 9 responders in OPSCC were HPV+.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526238059/0001193125-26-238059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526238059/crbp-20260526.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-238059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer